efgartigimod alfa   Click here for help

GtoPdb Ligand ID: 9777

Synonyms: ARGX-113 | efgartigimod alfa-fcab | Vyvgart®
Approved drug Immunopharmacology Ligand
efgartigimod alfa is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Efgartigimod alfa (ARGX-113) is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G (IgG) autoantibodies [6]. It binds to the IgG receptor, major histocompatibility complex class I-like Fc receptor (FcRn, the protein product of the FCGRT gene). Efgartigimod alfa inactivates FcRn's IgG binding ability (the FcRn-IgG interaction normally protects IgG from degradation) thus facilitating accelerated catabolism of native pathogenic autoantibodies [3,5]. The mechanism of this drug action is discussed more comprehensively in Roopenian and Akilesh (2007) [4] and Vaccaro et al. (2005) [7].
No information available.
Summary of Clinical Use Click here for help
The reference version of efgartigimod (efgartigimod alfa-fcab; ARGX-113) was advanced to clinical evaluations in patients with myasthenia gravis (MG), pemphigus vulgaris and primary immune thrombocytopenia. Click here to view ClinicalTrials.gov's registered ARGX-113 trials. ARGX-113 was granted FDA orphan drug designation for the treatment of MG in September 2017 [1]. In December 2021 the US FDA approved efgartigimod alfa-fcab (Vyvgart®) as a treatment for MG. EMA authorisation for Vyvgart® was issued in 2022.

Efgartigimod was further investigated for efficacy in the treatment of autoimmune encephalitis, autoimmune myositis. primary immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy (CIDP).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04687072 A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Phase 3 Interventional argenx
NCT04812925 A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Phase 3 Interventional argenx
NCT05979441 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy Phase 3 Interventional argenx
NCT07583641 A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults Phase 2 Interventional argenx